BioSpace News Archive

TrueBinding Inc. today announced top line results from its Phase 1b/2 proof-of-concept trial of TB006, an investigational monoclonal antibody against Galectin-3 for the treatment of mild to severe Alzheimer’s disease (AD) with baseline Mini Mental State Examination (MMSE) scores of 2-24).

Palisade Bio, Inc., a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, announced the appointment of Herbert B. Slade, MD, FAAAAI as Chief Medical Officer of Palisade Bio.

electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium.

Belite Bio, Inc (NASDAQ: BLTE) today announced that, following discussions with the FDA, it has finalized the study design for its planned Phase 3 clinical trial to evaluate efficacy and safety of Tinlarebant (a/k/a LBS-008) in patients with geographic atrophy (GA) associated with Dry AMD.

TFF Pharmaceuticals, Inc. announced that it has priced a $10.675 million underwritten offering of 9,282,609 shares of its common stock and warrants to purchase up to 4,641,305 shares of common stock.

Kintara Therapeutics, Inc.(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced data from three posters that are being presented at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting.

The company announced the first phase of the set of in vitro experiments designed to accomplish this validation was successful.

Silicon Catalyst, the world’s only incubator focused exclusively on accelerating semiconductor solutions, is pleased to announce that EXOKĒRYX has been accepted into the Silicon Catalyst Incubator program.

HiFiBiO Therapeutics announced today a second clinical trial supply agreement with Novartis to evaluate HiFiBiO’s HFB200603, a novel anti-BLTA monoclonal antibody in combination with tislelizumab, Novartis anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug Intelligence Science (DIS™) platform.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight.